复旦癌症研究连发两篇文章 发现两种癌症标记物

【字体: www.ebiotrade.com 时间:2009年03月02日 来源:生物通

编辑推荐:

  生物通报道,复旦大学附属中山医院肝癌研究所,复旦大学生物医学研究所的科学家在最近 一期的肝病权威杂志《Hepatology》杂志上连发两篇文章,介绍在肝癌方面的最新研究进展。

分享到:
  

生物通报道,复旦大学附属中山医院肝癌研究所,复旦大学生物医学研究所的科学家在最近 一期的肝病权威杂志《Hepatology》杂志上连发两篇文章,介绍在肝癌方面的最新研究进展。

 

文章通讯作者是复旦大学樊嘉教授,樊嘉教授现任中山医院副院长,肝外科主任,其领衔的项目“肝癌门静脉肺癌栓形成机制及多模式综合治疗技术”刚刚获得2008年度国家科技进步二等奖。去年,樊嘉教授曾在Cancer Research上发表肝癌研究成果,了解详情点击:http://www.ebiotrade.com/newsf/2008-11/20081120164128.htm

 

2月的Hepatology上樊嘉教授发表了两篇文章,第一篇Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma,解析肝癌细胞转移生物标记Capn4,详细报道见:

http://www.ebiotrade.com/newsf/2009-2/2009224165544.htm

 

新发表的文章以Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma为题,主要介绍肝小细胞癌的预后的诊断生物标记CD151c-Met

 

CD151已经被研究发现在多种肿瘤组织中具有促进转移的功能,而且在c-Met肝细胞生长信号通路中起作用。CD151在肝小细胞癌CD151/c-Met共表达的模式中发挥怎么样的功能却一直鲜为人知。

 

樊嘉教授领衔的研究小组通过综合的分析研究发现,CD151CD151/c-Met是两个独立的肝癌预后的指标。CD151与肝小细胞癌的癌转移侵袭有关联,是癌转移的生物标记。而CD151/c-Met是一个新型的预后指标,它还有可能成为一个新的治疗靶位。

 

(生物通 小茜)

 

生物通推荐原文检索:Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma

Abstract

It has been reported that tetraspanin CD151 acts as a promoter of metastasis in several tumors and plays an important role in c-Met/hepatocyte growth factor signaling. However, the role of CD151 alone and coexpression of CD151/c-Met in hepatocellular carcinoma (HCC) remains unclear. We found that expression of CD151 was positively related to metastatic potential of HCC cell lines, and modified cells with CD151high showed higher secretion of matrix metalloproteinase 9 and aggressiveness in vitro and higher metastatic ability in vivo. Furthermore, HCC patients with vascular invasion, large tumors, multiple tumors, high tumor-node-metastasis stage, and undifferentiated tumor were prone to have higher CD151 expression. The postoperative 3-, 5-, and 7-year overall survival (OS) of patients in HCCs with CD151high were significantly lower than those in the CD151low group, and correspondingly cumulative recurrence rates in HCCs with CD151high were significantly higher than those in the CD151low group. Both CD151 and c-Met were remarkably overexpressed in HCCs, compared with adjacent nontumorous and normal liver tissues. Pearson correlation analysis showed a slight correlation between CD151 and c-Met in HCCs. Importantly, the 5- and 7-year OS rates in CD151high/c-Methigh patients were 50.5% and 37.8%, respectively, significantly lower than those of CD151low/c-Metlow patients (63.9% and 54.6%, respectively). Five- and 7-year cumulative recurrence rates in CD151high/c-Methigh patients were 53.3% and 71.9%, respectively, markedly higher than those of CD151low/c-Metlow patients (39.0% and 52.5%, respectively). Multivariate analysis revealed that CD151 and combination of CD151/c-Met were independent prognostic indicators for OS and cumulative recurrence. Conclusion: CD151 is positively associated with invasiveness of HCC, and CD151 or combination of CD151/c-Met is a novel marker in predicting the prognosis of HCC and a potential therapeutic target。(生物通)

我来说两句(0)

[Ctrl+Enter]

加载读者评论......
  • 搜索
  • 国际
  • 国内
  • 人物
  • 产业
  • 热点
  • 科普
  • 急聘职位
  • 高薪职位

知名企业招聘

  • 国外动态
  • 国内进展
  • 医药/产业
  • 生态环保
  • 科普/健康

新闻专题

相关文章:

    加载相关文章......

今日文章:

    加载今日文章......

生物通首页 | 今日动态 | 生物通商城 | 人才市场 | 核心刊物 | 特价专栏 | BBS交流

版权所有 生物通

Copyright© eBiotrade.com, All Rights Reserved

联系信箱:

粤ICP备09063491号